s
s
s
Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug golimumab (Simponi) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Golimumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Golimumab Inhibitory Type 1 |
HCA240 |
AbD20710 |
Fab-FH1 |
2.3 |
PK bridging ELISA |
|
HCA241 |
AbD20692_hIgG1 |
Human IgG1 |
2.8 |
PK bridging ELISA ADA control |
||
HCA286 |
AbD254292 |
Fab-FH1 |
1.0 |
PK bridging ELISA |
||
HCA287 |
AbD25418_hIgG12 |
Human IgG1 HRP |
0.1 |
PK bridging ELISA ADA control |
||
Golimumab & Golimumab-TNFα Non-Inhibitory Type 2 |
HCA242 |
AbD20897 |
Fab-FH1 |
7 |
PK bridging ELISA |
|
HCA243 |
AbD20897_hIgG1 |
Human IgG1 |
7 |
PK bridging ELISA |
||
HCA289 |
AbD254552 |
Fab-FH1 |
0.9 |
PK bridging ELISA |
||
HCA290 |
AbD25451_hIgG12 |
Human IgG1 HRP |
0.4 |
PK bridging ELISA |
||
Golimumab-TNFα Complex Specific Type 3 |
HCA274 |
AbD257052 |
Fab-FH1 |
6 |
PK ELISA antigen capture format |
|
HCA245 |
AbD20893_hIgG1 |
Human IgG1 |
53 |
PK ELISA antigen capture format |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags
2 Affinity matured antibodies: HCA286 is derived from AbD20710 (HCA240); HCA287 is derived from AbD20692 (HCA241); HCA289 and HCA290 are derived from AbD20897 (HCA242); HCA274 is derived from AbD20893 (HCA245)
Type 1 anti-golimumab antibodies inhibit the binding of the drug golimumab to its target, tumor necrosis factor alpha (TNFα). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
The type 2 anti-golimumab antibodies bind to the golimumab idiotope, but do not inhibit the binding of golimumab to TNFα. They can therefore be used in a PK bridging ELISA to measure total drug - free, partially bound and fully bound.
The Type 3 antibodies specifically recognize the drug-target complex, detecting golimumab only when it is bound to TNFα. They are suitable as a detection antibody in a PK antigen capture assay.
Fig. 1. Golimumab PK bridging ELISA using antibodies HCA286 and HCA287P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Golimumab PK bridging ELISA using antibodies HCA289 and HCA290P.
Schematic image of PK bridging ELISA measuring total drug. Type 2 anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), drug target (red), type 2 anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 3. Golimumab PK antigen capture ELISA using antibody HCA274.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.
Fig. 4. Golimumab ADA bridging ELISA using antibody HCA287.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.